Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nipro's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was 円4,076 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円39,251 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Nipro's annualizedROC % for the quarter that ended in Mar. 2026 was 0.00%.
Nipro's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.04%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Nipro's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.58%.
Nipro (TSE:8086) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Nipro's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro EBIT Related Terms
Nipro EBIT Historical Data
* Premium members only.
The historical data trend for Nipro's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nipro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nipro's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円39,251 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (TSE:8086) has a EBIT of 円39,251 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nipro.
Is Nipro's EBIT too high?
Nipro's current EBIT is 円39,251 Mil. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's EBIT compare to ISRG and BDX?
Nipro's EBIT of 円39,251 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nipro. Nipro's current EBIT is 円39,251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current EBIT is 円39,251 Mil. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nipro (TSE:8086), the current EBIT is 円39,251 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
EBIT: 円39,251 Mil
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
